Gunderson Dettmer advised TeneoTwo on the deal. TeneoTwo, a developer of therapeutic antibodies, announced its pending acquisition by AstraZeneca, a bio-pharmaceutical company that focuses on the discovery,...
This content is for Standard 1 Year members only. LoginJoin Now